ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
Planchard, D., Reinmuth, N., Orlov, S., Fischer, J.R., Sugawara, S., Mandziuk, S., Marquez-Medina, D., Novello, S., Takeda, Y., Soo, R., Park, K., McCleod, M., Geater, S.L., Powell, M., May, R., Scheuring, U., Stockman, P., Kowalski, D.
Published in Annals of oncology (01.05.2020)
Published in Annals of oncology (01.05.2020)
Get full text
Journal Article
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
Yang, J.C.-H., Sequist, L.V., Zhou, C., Schuler, M., Geater, S.L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., Lu, S., Hirsh, V., Huang, Y., Sebastian, M., Okamoto, I., Dickgreber, N., Shah, R., Märten, A., Massey, D., Wind, S., Wu, Y.-L.
Published in Annals of oncology (01.11.2016)
Published in Annals of oncology (01.11.2016)
Get full text
Journal Article
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer
Mok, T.S., Geater, S.L., Iannotti, N., Thongprasert, S., Spira, A., Smith, D., Lee, V., Lim, W.T., Reyderman, L., Wang, B., Gopalakrishna, P., Garzon, F., Xu, L., Reynolds, C.
Published in Annals of oncology (01.08.2014)
Published in Annals of oncology (01.08.2014)
Get full text
Journal Article
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
Spigel, D., de Marinis, F., Giaccone, G., Reinmuth, N., Vergnenegre, A., Barrios, C.H., Morise, M., Felip, E., Andric, Z.G., Geater, S., Özgüroğlu, M., Mocci, S., McCleland, M., Enquist, I., Komatsubara, K.M., Deng, Y., Kuriki, H., Wen, X., Jassem, J., Herbst, R.S.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment
Kowalski, D.M., Reinmuth, N., Orlov, S.V., Fischer, J.R., Sugawara, S., Mandziuk, S., Medine, D.M., Novello, S., Takeda, Y., Soo, R.A., Park, K., McCleod, M., Geater, S.L., Powell, M., May, R., Stockman, P., Planchard, D.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC
Thongprasert, S., Geater, S.L., Clement, D., Abdelaziz, A., Reyes-Igama, J., Jovanovic, D., Alexandru, A., Schenker, M., Sriuranpong, V., Serwatowski, P., Suresh, S., Cseh, A., Gaafar, R.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
Reinmuth, N., Cho, B.C., Lee, K.H., Luft, A., Ahn, M.-J., Schneider, J., Shepherd, F.A., Geater, S.L., Pápai-Székely, Z., Van Ngoc, T., Garassino, M.C., Liu, F., Clemett, D., Thiyagarajah, P., Ouwens, M., Scheuring, U., Peters, S., Rizvi, N.
Published in Annals of oncology (01.04.2019)
Published in Annals of oncology (01.04.2019)
Get full text
Journal Article
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
Lin, C.-C., Taylor, M., Boni, V., Brunsvig, P.F., Geater, S.L., Salvagni, S., Garrido Lopez, P., Özgüroğlu, M., Sriuranpong, V., Ponce Aix, S., Ascierto, P.A., Fasolo, A., Sezer, A., Kowalski, D.M., Faris, J.E., Cameron, S., Mataraza, J., Wu, H., Antona, V., Ochoa de Olza, M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in ALK+ metastatic NSCLC (ASCEND-8)
Cho, B.C., Obermannova, R., Orlov, S.V., Batra, U., Geater, S.L., McKeage, M., Yang, C.-T., Postmus, P.E., de Castro, G., Kim, S.-W., De Marchi, P., Kanakasetty, G.B., Sriuranpong, V., Voon, P.J., Lau, Y.Y., Kiertsman, F., Passos, V.Q., Chen, Z., Dziadziuszko, R.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
127P LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Wonglhow, J., Sunpaweravong, P., Sathitruangsak, C., Lucien Geater, S., Dechaphunkul, A.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
Planchard, David, Jänne, Pasi A, Cheng, Ying, Yang, James C-H, Yanagitani, Noriko, Kim, Sang-We, Sugawara, Shunichi, Yu, Yan, Fan, Yun, Geater, Sarayut L, Laktionov, Konstantin, Lee, Chee K, Valdiviezo, Natalia, Ahmed, Samreen, Maurel, Jean-Marc, Andrasina, Igor, Goldman, Jonathan, Ghiorghiu, Dana, Rukazenkov, Yuri, Todd, Alex, Kobayashi, Kunihiko
Published in The New England journal of medicine (23.11.2023)
Published in The New England journal of medicine (23.11.2023)
Get full text
Journal Article
512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D., Jänne, P.A., Cheng, Y., Lee, C.K., Laktionov, K., Yang, T-Y., Yu, Y., Kato, T., Jiang, L., Chewaskulyong, B., Lucien Geater, S., Maurel, J-M., Rojas, C., Havel, L., Shepherd, F.A., Tanaka, K., Ghiorghiu, D., Armenteros Monterroso, E., Huang, X., Yang, J.C-H.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D., Jänne, P.A., Cheng, Y., Lee, C.K., Laktionov, K., Yang, T-Y., Yu, Y., Kato, T., Jiang, L., Chewaskulyong, B., Lucien Geater, S., Maurel, J-M., Rojas, C., Havel, L., Shepherd, F.A., Tanaka, K., Ghiorghiu, D., Armenteros Monterroso, E., Huang, X., Yang, J.C-H.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Cho, B.C., Luft, A., Alatorre Alexander, J.A., Lucien Geater, S., Laktionov, K., Sang-We, K., Ursol, G., Hussein, M., Lim Farah, L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Lai, Z., Mann, H., Shi, X., Peters, S., Garon, E.B., Mok, T.S.K., Johnson, M.L.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
P2.09-03 Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis
Reungwetwattana, T., Cho, B.C., Lee, K.H., Pang, Y.K., Fong, C.H., Kang, J.H., Lee, Y.-G., Lim, C.S., Danchaivijitr, P., Lim, Y.N., Lee, Y., How, S.H., Geater, S., Lee, S.S., Min, Y.J., Kim, J.-H., Lee, J.-S., Lee, G.-W., Soo, R.A., Choi, S., Lee, S.Y., Ahn, M.-J.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial
Cho, B.C. Chul, Kim, D-W., Batra, U., Park, K., Kim, S-W., Yang, C.T., Jye, V. Pie, Sriuranpong, V., Babu, K.G., Amin, K., Wang, Y., Wang, L., Bhering, M., Geater, S. Lucien
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
Reinmuth, N., Cho, B.C., Luft, A., Alexander, J.A. Alatorre, Geater, S. Lucien, Laktionov, K., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C-T., Araujo, L.H., Saito, H., Barrett, K., Lowery, C., Tattersfield, R., Peters, S., Garon, E.B., Mok, T.S.K., Johnson, M.L.
Published in Journal of thoracic oncology (01.04.2023)
Published in Journal of thoracic oncology (01.04.2023)
Get full text
Journal Article
474PAfatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC
Thongprasert, S, Geater, S L, Clement, D, Abdelaziz, A, Reyes-Igama, J, Jovanovic, D, Alexandru, A, Schenker, M, Sriuranpong, V, Serwatowski, P, Suresh, S, Cseh, A, Gaafar, R
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
Herbst, R.S., de Marinis, F., Giaccone, G., Reinmuth, N., Vergnenegre, A., Barrios, C.H., Morise, M., Felip, E., Andric, Z., Geater, S., Ozguroglu, M., Mocci, S., McCleland, M., Zou, W., Enquist, I., Komatsubara, K., Deng, Y., Kuriki, H., Spigel, D.R., Jassem, J.
Published in Annals of oncology (01.12.2019)
Published in Annals of oncology (01.12.2019)
Get full text
Journal Article
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Cho, B.C., Lee, K.H., Ahn, M.-J., Geater, S. Lucien, Ngoc, T.V., Wang, C.-C., Cho, E.K., Lee, J.S., Sriuranpong, V., Bui, Q., Clarke, S., Kuyama, S., Nakagawa, K., Liu, F., Clemett, D., Scheuring, U., Peters, S., Rizvi, N.
Published in Annals of oncology (01.11.2019)
Published in Annals of oncology (01.11.2019)
Get full text
Journal Article